

Substitute Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
13425-122001Application No.  
10/622,055**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.99(b))

Applicant  
Cernerud et al.Filing Date  
July 17, 2003Group Art Unit  
~~4614~~ 1624**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
ZT	AA	5,134,149	07/28/92	Carr, et al.	514	317	
ZT	AB	5,538,974	07/23/96	Ogawa et al.	514	253	
ZT	AC	6,143,792	11/07/00	Cattelin	514	640	
ZT	AD	6,358,977	03/19/02	Carlsson	514	317	

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
ZT	AE	EP 0522226A1	12/20/91	EPO	—	—		
ZT	AF	EP 0695545A1	06/14/95	EPO	—	—		
ZT	AG	WO 00/12090	03/09/00	WIPO	—	—		
ZT	AH	WO 01/89498 A2	11/29/01	WIPO	—	—		

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
ZT	AI	Abbot, F.V., et al., "Activation of 5-HT <sub>2A</sub> Receptors Potentiates Pain Produced by Inflammatory Mediators", <i>Neuropharmacology</i> , vol. 35(1), pp. 99-110, 1996.
ZT	AJ	Apelqvist, J., et al., "Ketanserin in the treatment of diabetic foot ulcer with severe peripheral vascular disease", <i>International Angiology</i> , vol. 9, pp. 120-124, 1990.
ZT	AK	Bush, L.R., et al., "The Role of the Endothelium in Arterial Thrombosis and the Influence of Antithrombotic Therapy", <i>Drug Development Research</i> , vol. 7, pp. 319-340, 1986.
ZT	AL	Cohen, M.L., "Canine, but not rat bladder contracts to serotonin via activation of 5HT <sub>2</sub> receptors", <i>The Journal of Urology</i> , vol. 143, pp. 1037-1040, 1990.
ZT	AM	Costagliola, C., et al., "Effect of tropical ketanserin administration on intraocular pressure", <i>British Journal of Ophthalmology</i> , vol. 77, pp. 344-348, 1993.
ZT	AN	Danton, G., et al., "Endothelium-targeted pharmacotherapeutics for the treatment of stroke", <i>Current Opinion in Investigational Drugs</i> , vol. 3(6), pp. 896-904, 2002.
ZT	AO	Dietrich, W.D., et al., "Effect of the serotonin antagonist ketanserin on the hemodynamic and morphological consequences of thrombotic infarction", <i>Journal of Cerebral Blood Flow and Metabolism</i> , vol. 9, pp. 812-820, 1989.
ZT	AP	Dursun, S.M., et al., "An exploratory approach to the serotonergic hypothesis of depression: bridging the synaptic gap", <i>Medical Hypotheses</i> , vol. 56(2), pp. 235-243, 2001.
ZT	AQ	Furukawa, K., et al., "Therapeutic effects of sarpogrelate hydrochloride (MCI-9042) on chronic arterial occlusive diseases: a double-blind comparison with ticlopidine hydrochloride", <i>J. Clin. Ther. Med.</i> 1991, 7, 1747-1770.
ZT	AR	Gelders, Y.G., "Thymosthenic agents, a novel approach in the treatment of schizophrenia", <i>British Journal of Psychiatry</i> , vol. 155(suppl.), pp. 33-36, 1989.

Examiner Signature


Date Considered

21 AUGUST 2006

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-122001	Application No. 10/622,055
	Applicant Cernerud et al.		
	Filing Date July 17, 2003	Group Art Unit <del>1614</del> 1624	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
ZT	AS	Hara, N., et al., "Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models", <i>Thrombosis and Haemostasis</i> , vol. 66(4), pp. 484-488, 1991.
ZT	AT	Hemmeter, U., et al., "Schlafstorungen bei chronischen schmerzen und generalisierter tendomyopathie", <i>Schweiz Med Wochenschr</i> , vol. 125, pp. 2391-2397, 1995. (Abstract Only)
ZT	AU	Hotta, N., et al., "Effects of the 5-HT <sub>2A</sub> receptor antagonist sarpogrelate in diabetic patients with complications", <i>Clin Drug Invest</i> , vol. 18(3), pp. 199-207, 1999.
ZT	AV	Ichiiyanagi, N., et al., "Changed responsiveness of the detrusor in rabbits with alloxan induced hyperglycemia: Possible role of 5-hydroxytryptamine for diabetic bladder dysfunction", <i>The Journal of Urology</i> , vol. 168, pp. 303-307, 2002.
ZT	AW	Ishimura, E., et al., "Therapeutic effect of sarpogrelate, a new 5-hydroxytryptamine receptor 2A antagonist, on diabetic nephropathy and neuropathy", <i>Nephron</i> , vol. 76, pp. 227-229, 1997.
ZT	AX	Jackson, J., et al., "Enhancement of [m-methoxy 3H]MDL100907 binding to 5HT <sub>2A</sub> receptors in cerebral cortex and brain stem of streptozotocin induced diabetic rats", <i>Molecular and Cellular Biochemistry</i> , vol. 199, pp. 81-85, 1999.
ZT	AY	Kaplan, S.A., et al., "Urodynamic findings in patients with diabetic cystopathy", <i>The Journal of Urology</i> , vol. 153, pp. 342-344, 1995.
ZT	AZ	Kihara, H., et al., "Antithrombotic activity of AT-1015, a potent 5-HT <sub>2A</sub> receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time", <i>European Journal of Pharmacology</i> , vol. 433, pp. 157-162, 2001.
ZT	AAA	Kim, H.J., et al., "Acute effects of serotonin on rat bladder contractility", <i>Urologia Internationalis</i> , vol. 68, pp. 44-48, 2002.
ZT	ABB	Kobori, S., et al., "Effect of 5-hydroxytryptamine <sub>2A</sub> receptor antagonist on the development of diabetic nephropathy in early stage", <i>Diabetes Mellitus: Recent Advances for the 21<sup>st</sup> Century</i> , pp. 283-286, 2000.
ZT	ACC	Kodama, M., et al., "Influence of 5-hydroxytryptamine and the effect of a new serotonin receptor antagonist (sarpogrelate) on detrusor smooth muscle of streptozotocin-induced diabetes mellitus in the rat", <i>International Journal of Urology</i> , vol. 7, pp. 231-235, 2000.
ZT	ADD	Leysen, D., et al., "5-HT <sub>2</sub> antagonists: a concept for the treatment of schizophrenia", <i>Current Pharmaceutical Design</i> , vol. 3, pp. 367-390, 1997.
ZT	AEE	Malyszko, J., et al., "Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes", <i>Thrombosis Research</i> , vol. 75(5), pp. 569-576, 1994.
ZT	AFF	Mano, T., et al., "The effect of anplag (sarpogrelate HCl), new selective 5-HT <sub>2</sub> antagonist on intraocular pressure in rabbits", <i>Investigative Ophthalmology &amp; Visual Science</i> , vol. 36(4), pp. 3322-3309, 1995.
ZT	AGG	Martinez-De Jesus, F.R., et al., "Randomized single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers", <i>Archives of Medical Research</i> , vol. 28(1), pp. 95-99, 1997.
ZT	AHH	Menendez, V., et al., "Urodynamic evaluation in simultaneous insulin-dependent diabetes mellitus and end stage renal disease", <i>The Journal of Urology</i> , vol. 155, pp. 2001-2004, 1996.
ZT	AII	Mermoud, A., et al., "Le traitement du glaucome a pression normale avec un antagoniste des recepteurs S2 de la serotonine, le naftidrofuryl (praxilen)", <i>Klin. Mbl. Augenheilk.</i> , vol. 198, pp. 332-334, 1991.
ZT	AJJ	Mermoud, A., et al., "Double-blind study in the treatment of normal tension glaucoma with naftidrofuryl", <i>Ophthalmologica</i> , vol. 201, pp. 145-151, 1990.

Examiner Signature 	Date Considered 21 AUGUST 2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-122001	Application No. 10/622,055
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Cernerud et al.	
		Filing Date July 17, 2003	Group Art Unit <del>1614</del> 1624

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
ZT	AKK	Nabeshima, T., et al., "Effect of naftidrofuryl oxalate on 5-HT <sub>2</sub> receptors in mouse brain: evaluation based on quantitative autoradiography and head-twitch response", <i>European Journal of Pharmacology</i> , vol. 223, pp. 109-115, 1992.
ZT	ALL	Obata, H., et al., "Antinociception in rat by sarpogrelate, a selective 5-HT <sub>2A</sub> receptor antagonist, is peripheral", <i>European Journal of Pharmacology</i> , vol. 404, pp. 95-102, 2000.
ZT	AMM	Ogawa, S., et al., "The 5-HT <sub>2</sub> receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients", <i>Clinical and Experimental Pharmacology and Physiology</i> , vol. 26, pp. 461-464, 1999.
ZT	ANN	Otake, T., et al., "Bone atrophy in complex regional pain syndrome patients measured by microdensitometry", <i>Canadian Journal of Anesthesiology</i> , vol. 45(9), pp. 831-838, 1998.
ZT	AOO	Pietraszek, M.H., et al., "Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus", <i>Thrombosis Research</i> , vol. 66, pp. 765-774, 1992.
ZT	APP	Pietraszek, M.H., et al., "Enhanced platelet response to serotonin in diabetes mellitus in relationship to vascular complications", <i>Thromb. Haemost.</i> 1991, 65, 985 (Abstract Only)
ZT	AQQ	Pietraszek, M.H., et al., "The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus", <i>Thrombosis Research</i> , vol. 70, pp. 131-138, 1993.
ZT	ARR	Radulovacki, M., et al., "Ketanserin, a 5-HT <sub>2</sub> receptor antagonist, reduces sleep apneas in rats", <i>Research Communications in Biological Psychology and Psychiatry</i> , vol. 26 (1,2), 2001.
ZT	ASS	Robertson, S.C., et al., "Effects of serotonin (5-HT) and selective 5-HT receptor antagonists on regional cerebral blood flow after middle cerebral artery occlusion", <i>Surgical Forum</i> , pp. 561-563.
ZT	ATT	Saxena, P.R., et al., "Excitatory 5-hydroxytryptamine receptors in the cat urinary bladder are of the M- and 5-HT <sub>2</sub> -type", <i>Journal of Autonomic Pharmacology</i> , vol. 5, pp. 101-107, 1985.
ZT	AUU	Schechter, L.E., et al., "Serotonergic antidepressants: current and future perspectives", <i>CPNS Investigational Drugs</i> , vol. 7(4), pp. 432-447, 1999.
ZT	AVV	Sorbera, L.A., et al., "MDL-100907", <i>Drugs of the Future</i> , vol. 23(9), pp. 955-965, 1998.
ZT	AWW	Stratz, T., et al., "Blockierung der 5-HT <sub>2</sub> -rezeptoren – ein neues behandlungsspringzip der generalisierten tendomyopathie (fibromyalgie)?", <i>Zeitschrift für Rheumatologie</i> , vol. 50, pp. 21-22, 1991. (Abstract Only)
ZT	AXX	Sugimoto, S., et al., "Characteristics of 5-HT <sub>2A</sub> receptors in the bladder smooth muscle of diabetic rats", <i>Nihon. Univ. J. Med.</i> , vol. 43, pp. 141-152, 2001.
ZT	AYY	Sumiyoshi, T., et al., "The effect of streptozotocin-induced diabetes on dopamine <sub>2</sub> , serotonin 1A, and serotonin 2A receptors in the rat brain", <i>Neuropsychopharmacology</i> , vol. 16(3), 183-190, 1997.
ZT	AZZ	Takei, I., et al., "Effects of the 5-HT <sub>2</sub> receptor antagonist sarpogrelate on diabetic vascular disease", <i>Diabetes Research</i> , vol. 34, pp. 239-246, 1999.
ZT	AAAA	Takenaka, H., et al., "The effect of anglag (sarpogrelate HCL), novel selective 5-HT <sub>2</sub> antagonist on intraocular pressure in glaucoma patients", <i>Invest. Ophthalmol. Vis. Sci.</i> 1995, 36, S734. (Abstract Only)
ZT	ABBB	Takimoto, Y., et al., "The effect of 5-HT <sub>2</sub> antagonist for urinary frequency symptom on diabetes mellitus patients", <i>Jpn. J. Urol.</i> vol. 90(8), pp. 731-740, 1999. (Abstract Only)
ZT	ACCC	Tammela, T.L.J., et al., "Temporal changes in micturition and bladder contractility after sucrose diuresis and streptozotocin-induced diabetes mellitus in rats", <i>The Journal of Urology</i> , vol. 153, pp. 2014-2021, 1995.

Examiner Signature 	Date Considered 21 AUGUST 2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-122001	Application No. 10/622,055
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Cernerud et al.	
		Filing Date July 17, 2003	Group Art Unit <del>1614</del> 1624

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
ET	ADDD	Tokunaga, A., et al., "5-HT <sub>2A</sub> receptor subtype is involved in the thermal hyperalgesic mechanism of serotonin in the periphery", <i>Pain</i> , vol. 76, pp. 349-355, 1998.
ET	AEEE	Viola, A.U., et al., "Ritaserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers", <i>Clinical Neurophysiology</i> , vol. 113, pp. 429-434, 2002.
ET	AFFF	Weinberger, D.R., et al., "Cognitive function in schizophrenia", <i>International Clinical Psychopharmacology</i> , vol. 12(supp.), pp. S29-S36, 1997.
ET	AGGG	Yoshida, A., et al., "5-hydroxytryptamine receptors, especially the 5-HT <sub>4</sub> receptor, in guinea pig urinary bladder", <i>Jpn. J. Pharmacol.</i> , vol. 89, pp. 349-355, 2002.

Examiner Signature 	Date Considered 21 AUGUST 2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	